We make smarter supplements that are proven to work. Brighter days, more tomorrows. Reach your Heights.
Business overview
Location | London, United Kingdom |
---|---|
Social media | |
Website | www.yourheights.com |
Sectors | Healthcare Mixed Digital/Non-Digital B2C |
Company number | 08403776 |
Incorporation date | 14 Feb 2013 |
Investment summary
Business highlights
- Developed by scientists, trusted by experts
- Over £11M ARR* and 40,000 monthly orders
- Thousands of 5* reviews, trusted by elite athletes
- 2 products → 5+ and EU expansion in next 2 years
Pitch
About the Campaign
Heights is transforming brain and gut health with science-backed supplements designed by top neuroscientists and dietitians. With £11M ARR* and 40,000+ monthly orders, we’re just getting started.
Join the wellness revolution.
Market Opportunity
Modern life, stress, gut issues and nutrient deficiencies stop people reaching their potential.
Preventative health is surging,with the supplement market set to grow as much as 70% by 2030 (Grandview Supplement Market Research, 2023).
Developed by experts, Heights science-backed supplements help twenty-seven thousand people get back on track daily, feel their best and reach their goals.
Traction & Key Accomplishments
Heights is rapidly growing, with over £11M ARR (based on the revenue for Aug 24)* and 40,000+ subscriptions despite focusing on just two products in one market. We’ve seen a 30% increase in sales in just three months (May 2024-Aug 2024)*.
Our success is evident in thousands of 5 star reviews, over 60 press features since January 2024, and trusted partnerships with elite sports teams.
* Based on unaudited management accounts. Past performance is not an indication of future performance. ARR = Annual Run Rate: the monthly revenue for the month multiplied by 12.
Use of Funds
This funding will help Heights on their mission to be placed as a key player in the booming brain & gut health market. Funds will fuel product expansion, market launches and scientific research.
50% for new product development
30% for expansion into European market
20% for clinical trials
Key Information
Outstanding Debt
The company has the following outstanding debt:
A loan of £50,000 from Barclays bank with an interest rate of 2.5%. The loan is repaid in monthly instalments of £833.33, with the final payment due in 12/2026.
The funds raised from this round will not be used to repay this loan.
Share Classes
The company has two classes of shares, A Ordinary shares (which are only held by the founders) and Ordinary shares (which are held by all other shareholders, including Seedrs). The A ordinary shares give the founders, in aggregate, 50.1% of the voting rights attached to all shares in the company.
Open an account to get access to the team members of Heights
Already have an account? Log in
To comply with financial regulations, we can only show full campaign details to registered users.
Only shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy sharesOnly shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy sharesOnly shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy sharesOnly shareholders can access this page
If you successfully purchase a share lot of this business, you will be granted access.
Buy shares